Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new WWARN study, published in BMC Medicine, supports a World Health Organization (WHO) recommendation that a single primaquine target dose of 0.25 mg/kg is generally safe and well tolerated when given together with an ACT to treat malaria.

Woman carrying a child, in a limited-resource settlement in Kenya © Peter Kapuscinski, World Bank

Primaquine has been available for more than 70 years and millions of doses have been administered over the years, but safety outcomes have not been well documented.

The WHO changed its guidelines to lower the dosage of primaquine in 2012, to accelerate malaria elimination efforts and avoid the spread of artemisinin resistance. However, uptake of the recommendation has been slow due to safety concerns among those with G6PD deficiency. G6PD deficiency is an inherited enzyme deficiency that is particularly common in some malaria endemic areas that makes red blood cells more likely to break down.

Researchers performed a systematic review and an individual patient data (IPD) meta-analysis of single dose (SD) primaquine studies for Plasmodium falciparum malaria with the aim of establishing the safety of SD primaquine, improving uptake and potentially setting guidelines for the implementation of weight or age-based dosing bands. The data included 20 studies of 6,406 participants, of which over 80% had received a single target dose of primaquine ranging between 0.0625 and 0.75 mg/kg. There was no effect of primaquine on haemoglobin concentrations (a measure for anaemia) in G6PD normal participants, and only a small effect on haemoglobin among the 194 G6PD-deficient African participants given a 0.25 mg/kg primaquine target dose.

The authors said the results could now reassure national malaria control programmes that were considering the use of SD primaquine to advance malaria elimination or reduce the spread of artemisinin resistance.

The full story is available on the WWARN website.

Read the full paper 'Safety of single dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data' on the BMC Medicine website

Similar stories

Study finds almost two-thirds of patients are systematically excluded from drug trials

A new WWARN study has found that nearly two-thirds of the malaria-positive patients who present to health facilities are systematically excluded from “classical” anti-malarial treatment efficacy trials.

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Shobhana Nagraj, Women in Science

Clinical Researcher Shobhana Nagraj, from the Health Systems Collaboratives in Oxford, tells us about the female role models who inspired her to follow her dreams

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Expert Comment: Biotechnology allows us to make unprecedented interventions for conservation

In the wake of high-profile reports on the devastating toll human activity has had on global biodiversity, nations are expected to adopt the Convention on Biodiversity post-2020 framework that outlines measures to ensure humans live in harmony with nature.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.